No annual revenue total was found in FibroBiologics, Inc.'s SEC filings.
FibroBiologics, Inc. (FBLG) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$16.7 million. As of Jun 30, 2026 it held $3.5 million in cash and investments and $1.3 million in total debt.
Revenue
—
Net income (TTM)
$-18.14M
-37.2% vs year-ago TTM
Operating cash flow (TTM)
$-14.79M
+1.0% vs year-ago TTM
Free cash flow (TTM)
$-14.80M
+3.3% vs year-ago TTM
EPS (TTM)
$-0.39
+46.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
67.59M
+79.1% vs prior year
Net cash
$2.18M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- FBLG (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1958777
- Former names
- FibroBiologics Inc. (until Feb 6, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
|---|---|---|---|
| Operating income | -$16.6M | -$13.7M | -$8.9M |
| Net income | -$18.6M | -$11.2M | -$16.5M |
| Diluted EPS | -$0.42 | -$0.34 | -$0.68 |
| Operating cash flow | -$16.4M | -$11.9M | -$6.4M |
| Free cash flow | -$16.7M | -$12.1M | -$6.9M |
| Total assets | $9.6M | $16.4M | $11.8M |
| Total liabilities | $3.5M | $13.7M | $10.6M |
| Stockholders' equity | $6.2M | $2.7M | $1.3M |
| Cash and investments | $4.9M | $14.0M | $9.2M |
| Total debt | $2.4M | $1.4M | $1.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Oct 8, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Shareholder vote results, Regulation FD disclosure
|
Sep 18, 2026 | Sep 17, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Sep 15, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Aug 24, 2026 | Aug 20, 2026 |
| 10-Q | Quarterly report | Jul 31, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Listing notice
|
Jul 24, 2026 | Jul 22, 2026 |
All 242 FibroBiologics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.